Is a company that develops and commercializes novel treatments for B-cell diseases
The stock initiated a bull trend at the end of 2023 after a breakaway gap and has gained +90% during 2024 and gave 2 opportunities to buy on breakouts
Now is forming a 3rd base and may give another opportunity to enter, all this while relative to its sector
XLV is making new highs
According to IBD is not among the industry leaders, but it has a 96 Relative Strength Rating against the
SPX
The stock initiated a bull trend at the end of 2023 after a breakaway gap and has gained +90% during 2024 and gave 2 opportunities to buy on breakouts
Now is forming a 3rd base and may give another opportunity to enter, all this while relative to its sector
XLV is making new highsAccording to IBD is not among the industry leaders, but it has a 96 Relative Strength Rating against the
SPX
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.